Content
12/09/2024
San Mateo, CA USA
Cala Health
completed $50 million Growth Round funding. Investors include
Vertex Growth (lead), Nexus NeuroTech Ventures (lead), Action Potential Venture Capital, Ascension Ventures, Google Ventures, Johnson & Johnson Innovation, Lightstone Ventures, Lux Capital, OSF Ventures, Peak6, Reimagined Ventures, Triventures.
About
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health's lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in Parkinson's disease and other indications in neurology, as well as targets in psychiatry, cardiology and autoimmune disorders. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
